1-acetyl-3-(benzo[d][1,3]dioxol-5-yl)-5-phenyl-4,5-dihydro-1H-pyrazole | 1204141-62-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 英文名称: 1-acetyl-3-(benzo[d][1,3]dioxol-5-yl)-5-phenyl-4,5-dihydro-1H-pyrazole
• 英文别名: 1-acetyl-3-(3,4-methylenedioxyphenyl)-5-phenyl-4,5-dihydropyrazole；1-[5-(1,3-Benzodioxol-5-yl)-3-phenyl-3,4-dihydropyrazol-2-yl]ethanone
• CAS: 1204141-62-7
• 化学式: C₁₈H₁₆N₂O₃
• 分子量: 308.337
• InChiKey: GYZODYBYQGDNPY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  51.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-acetyl-3-(benzo[d][1,3]dioxol-5-yl)-5-phenyl-4,5-dihydro-1H-pyrazole 在 三溴化硼 、 甲醇 作用下， 以 二氯甲烷 为溶剂， 以37%的产率得到1-acetyl-3-(3,4-dihydroxyphenyl)-5-phenyl-4,5-dihydropyrazole
  参考文献：
  名称：

  [EN] NEW DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES
  [FR] NOUVEAU MÉDICAMENT POUR L'INHIBITION DE L'AGRÉGATION DES PROTÉINES IMPLIQUÉES DANS DES MALADIES ASSOCIÉES À L'AGRÉGATION DES PROTÉINES ET/OU DES MALADIES NEURODÉGÉNÉRATIVES

  摘要：

  公开号：

  WO2010000372A3
• 作为产物：
  描述：

  3,4-亚甲二氧苯乙酮 在 一水合肼 、 sodium hydroxide 作用下， 以 乙醇 为溶剂， 反应 24.0h， 生成 1-acetyl-3-(benzo[d][1,3]dioxol-5-yl)-5-phenyl-4,5-dihydro-1H-pyrazole
  参考文献：
  名称：

  1-取代的3-芳基-5-芳基(杂芳基)-2-吡唑啉的合成及其抗肿瘤活性研究

  摘要：

  合成了三个系列的新型 1,3,5-三取代 2-吡唑啉衍生物，其中含有噻吩和苯并二氧杂环戊烷作为潜在的抗肿瘤剂。获得的化合物的体外抗肿瘤活性在美国国家癌症研究所 (NCI) 进行了测定。5-(benzo[d][1,3]dioxol-5-yl)-3-(4-甲氧基苯基)-4,5-dihydro-1H-pyrazole-1-carbothioamide (9a) 是最突出的由于其对白血病 (RPMI-8226)、肾癌 (UO-31) 和前列腺癌 (DU-145) 细胞系具有显着的活性，GI50 值分别为 1.88、1.91 和 1.94 µM。

  DOI：

  10.1002/ardp.201100170

文献信息

• NEW DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES
  申请人：Giese Armin

  公开号：US20110293520A1

  公开（公告）日：2011-12-01

  The present invention relates to a compound represented by formula (E). The present invention also relates to a compound represented by the formula (E) for use in the treatment or prevention of diseases linked to protein aggregation and/or neurodegenerative diseases. Moreover, the present invention relates to pharmaceutical and diagnostic compositions comprising the compound of the invention as well as to a kit. Furthermore, the present invention relates to a method of imaging deposits of aggregated protein. A kit for preparing a detectably labelled compound of the present invention is also disclosed. Formula (E) wherein X, Y and L are independently nondirectionally selected from —C(R 1 )(R 2 )—, —C(R 3 )═, —N(R 4 )—, —N═, —N + (R 5 )═, —O— and —S—; M and Z are independently nondirectionally selected from formula (I) and formula (II).

  本发明涉及一种由公式（E）表示的化合物。本发明还涉及一种由公式（E）表示的化合物，用于治疗或预防与蛋白质聚集和/或神经退行性疾病相关的疾病。此外，本发明涉及包含本发明化合物的制药和诊断组合物，以及一种试剂盒。此外，本发明还涉及一种成像聚集蛋白沉积物的方法。还公开了一种用于制备可检测标记的本发明化合物的试剂盒。公式（E）中，X、Y和L分别独立地从—C（R1）（R2）—、—C（R3）═、—N（R4）—、—N═、—N+（R5）═、—O—和—S—中非定向选择；M和Z分别独立地从公式（I）和公式（II）中非定向选择。
• DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES
  申请人：Ludwig-Maximilians-Universität München

  公开号：US20160185730A1

  公开（公告）日：2016-06-30

  The present invention relates to a compound represented by formula (E). The present invention also relates to a compound represented by the formula (E) for use in the treatment or prevention of diseases linked to protein aggregation and/or neurodegenerative diseases. Moreover, the present invention relates to pharmaceutical and diagnostic compositions comprising the compound of the invention as well as to a kit. Furthermore, the present invention relates to a method of imaging deposits of aggregated protein. A kit for preparing a detectably labelled compound of the present invention is also disclosed.

  本发明涉及一种由式(E)所表示的化合物。本发明还涉及一种由式(E)所表示的化合物，用于治疗或预防与蛋白质聚集和/或神经退行性疾病有关的疾病。此外，本发明还涉及包含本发明化合物的制药和诊断组合物，以及一种试剂盒。此外，本发明还涉及一种成像聚集蛋白沉积物的方法。还公开了一种用于制备本发明化合物的可检测标记试剂盒。
• Drugs for inhibiting aggregation of proteins invoved in diseases linked to protein aggregation and/or neurodegenerative diseases
  申请人：Ludwig-Maximilians-Universität München

  公开号：EP2687513A1

  公开（公告）日：2014-01-22

  The present invention relates to a compound represented by formula (E). The present invention also relates to a compound represented by the formula (E) for use in the treatment or prevention of diseases linked to protein aggregation and/or neurodegenerative diseases. Moreover, the present invention relates to pharmaceutical and diagnostic compositions comprising the compound of the invention as well as to a kit. Furthermore, the present invention relates to a method of imaging deposits of aggregated protein. A kit for preparing a detectably labelled compound of the present invention is also disclosed.

  本发明涉及一种由式（E）代表的化合物。本发明还涉及一种由式（E）代表的化合物，用于治疗或预防与蛋白质聚集相关的疾病和/或神经退行性疾病。此外，本发明还涉及包含本发明化合物的药物和诊断组合物以及试剂盒。此外，本发明还涉及一种对聚集蛋白沉积物成像的方法。本发明还公开了一种用于制备可检测标记的本发明化合物的试剂盒。
• Drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases
  申请人：Ludwig-Maximilians-Universität München

  公开号：US10071966B2

  公开（公告）日：2018-09-11

  The present invention relates to a compound represented by formula (E). The present invention also relates to a compound represented by the formula (E) for use in the treatment or prevention of diseases linked to protein aggregation and/or neurodegenerative diseases. Moreover, the present invention relates to pharmaceutical and diagnostic compositions comprising the compound of the invention as well as to a kit. Furthermore, the present invention relates to a method of imaging deposits of aggregated protein. A kit for preparing a detectably labelled compound of the present invention is also disclosed.

  本发明涉及一种由式（E）代表的化合物。本发明还涉及一种由式（E）代表的化合物，用于治疗或预防与蛋白质聚集相关的疾病和/或神经退行性疾病。此外，本发明还涉及包含本发明化合物的药物和诊断组合物以及试剂盒。此外，本发明还涉及一种对聚集蛋白沉积物成像的方法。本发明还公开了一种用于制备可检测标记的本发明化合物的试剂盒。
• NEW DRUGS FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES
  申请人：Ludwig-Maximilians-Universität München

  公开号：EP2307381A2

  公开（公告）日：2011-04-13